Clinical Trials Logo

Clinical Trial Summary

This is a Phase 3, two-arm, randomized, double-blind, placebo-controlled, single dose efficacy and safety study evaluating the use of a nasal gel to prevent nausea and vomiting associated with motion


Clinical Trial Description

Eligible participants will be randomized 1:1 to DPI-386 Nasal Gel or matching placebo nasal gel and assigned a time and date for travel on an ocean vessel. Participants will be asked to self-administer the study medication while the ship is in harbor. The Modified Performance Self-Assessment Questionnaire (mPSAQ) will be completed by each participant prior to the administration of nasal gel, approximately every 30 minutes of travel, and at the end of travel. The participants will complete the Nausea Assessment Scale (NAS) every 30 minutes afer dosing, and at the end of travel. The participants will also be asked to complete a Sopite Assessment Questionnaire (SAQ) and a Patient Global Assessment of Severity (PGI-S) at 4 hours to describe their travel experience. All questionnaires will be submitted for analysis. An exit interview will also be conducted. The treatment phase will last approximately 4-5 hours ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04947423
Study type Interventional
Source Repurposed Therapeutics, Inc.
Contact
Status Completed
Phase Phase 3
Start date June 14, 2021
Completion date August 12, 2021

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Recruiting NCT06128707 - Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study
Completed NCT05611814 - Preliminary Evaluation of an Osteopathic Manipulative Treatment (OMT) to Prevent Motion Sickness Symptoms N/A
Recruiting NCT06106256 - Three-Axis Wearable Adaptive Vestibular Stimulator N/A
Completed NCT02839135 - A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants. Phase 1
Completed NCT04420949 - Sensory Training for Visual Motion Sickness N/A
Completed NCT04184115 - Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness Phase 3
Completed NCT03988530 - Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects Phase 3
Terminated NCT04219982 - DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness Phase 2/Phase 3
Terminated NCT02155309 - Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray Phase 2/Phase 3
Recruiting NCT05903924 - Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness Phase 3
Recruiting NCT04999449 - Nebulizer Delivery of Intranasal Scopolamine Phase 1
Recruiting NCT05886660 - Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance Phase 2
Completed NCT03755596 - Clinical Evaluation of the Use of Ginger Extract in the Management of Motion Sickness Phase 4
Recruiting NCT05628220 - Motion Sickness Desensitization Using VR N/A
Recruiting NCT06138613 - Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness Phase 3
Completed NCT04327661 - Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness Phase 3
Completed NCT06232785 - Gynecologic Endoscopic Surgery of Female Motion Sickness Patients Phase 4
Completed NCT06056622 - Motion Sickness Rehabilitation for Virtual Reality N/A
Withdrawn NCT04331561 - Sensory Training for Orientation and Balance N/A